新天药业(002873) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 193,151,214.98, representing an increase of 8.93% compared to CNY 177,321,934.57 in the same period last year[5]. - Net profit attributable to shareholders decreased by 73.11% to CNY 4,187,454.45 from CNY 15,571,957.55 year-on-year[5]. - The net profit after deducting non-recurring gains and losses fell by 81.21% to CNY 2,765,376.35 compared to CNY 14,715,210.15 in the previous year[5]. - Basic earnings per share dropped by 74.44% to CNY 0.0172 from CNY 0.0673 in the same period last year[5]. - Total operating revenue for the current period reached ¥193,151,214.98, an increase of 8.3% compared to ¥177,321,934.57 in the previous period[17]. - Net profit for the current period was ¥4,187,454.45, a decrease of 73.1% compared to ¥15,571,957.55 in the previous period[18]. - Basic earnings per share decreased to ¥0.0172 from ¥0.0673, reflecting a significant decline in profitability[18]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 22.43% to CNY 15,986,135.81 from CNY 20,608,457.90 year-on-year[5]. - Cash flow from operating activities generated a net amount of ¥15,986,135.81, down 22.5% from ¥20,608,457.90 in the previous period[20]. - The company reported a net cash outflow from financing activities of CNY -22,937,787.36, a significant increase in outflow compared to CNY -4,751,467.96 in the previous year[9]. - The company experienced a net cash outflow from financing activities of ¥22,937,787.36, worsening from an outflow of ¥4,751,467.96 in the previous period[22]. - The company's cash and cash equivalents decreased from CNY 118,164,427.88 to CNY 99,758,021.83, a decline of approximately 15.5%[14]. - Cash and cash equivalents at the end of the period totaled ¥99,758,021.83, a decrease from ¥140,605,931.76 at the end of the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,917,497,598.80, a decrease of 1.69% from CNY 1,950,501,320.49 at the end of the previous year[5]. - Total current assets decreased from CNY 616,807,046.83 to CNY 588,809,486.84, a decline of about 4.5%[14]. - Total liabilities decreased from CNY 755,785,472.79 to CNY 718,594,296.65, a reduction of approximately 4.9%[16]. - The total assets decreased from CNY 1,950,501,320.49 to CNY 1,917,497,598.80, a decline of approximately 1.7%[14]. - The company's retained earnings increased from CNY 563,396,301.30 to CNY 567,583,755.75, reflecting a growth of about 0.4%[16]. - The total equity attributable to the parent company increased slightly from CNY 1,194,715,847.70 to CNY 1,198,903,302.15, an increase of approximately 0.3%[16]. Borrowings and Financing - Short-term borrowings decreased by 60.44% to CNY 121,134,180.55 from CNY 306,242,291.69, reflecting a repayment of bank loans[9]. - Long-term borrowings increased significantly from CNY 221,400,000.00 to CNY 391,880,000.00, an increase of about 77%[16]. - The company's short-term borrowings decreased significantly from CNY 306,242,291.69 to CNY 121,134,180.55, a reduction of about 60.5%[16]. Research and Development - Research and development expenses increased by 74.89% to CNY 9,153,093.49 from CNY 5,233,578.17 year-on-year, indicating a significant investment in innovation[9]. - Research and development expenses increased to ¥9,153,093.49, up 74.5% from ¥5,233,578.17, indicating a focus on innovation[17]. Inventory and Receivables - Accounts receivable increased from CNY 308,443,933.77 to CNY 319,507,090.39, reflecting a growth of about 3.4%[14]. - Inventory decreased from CNY 145,478,159.62 to CNY 129,515,012.25, a reduction of approximately 11%[14]. - Sales expenses rose to ¥84,366,283.27, an increase of 9.6% compared to ¥77,379,857.99 in the previous period[17].